Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET Journal Article
| Authors: | Straus, D. J.; Johnson, J. L.; LaCasce, A. S.; Bartlett, N. L.; Kostakoglu, L.; Hsi, E. D.; Schoder, H.; Hall, N. C.; Jung, S. H.; Canellos, G. P.; Schwartz, L. H.; Takvorian, R. W.; Juweid, M. E.; Cheson, B. D. |
| Article Title: | Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET |
| Abstract: | To reduce doxorubicin, bleomycin, vinblastine and dacarbazine toxicity, the Cancer and Leukemia Group B conducted a phase 2 trial of doxorubicin, vinblastine, and gemcitabine for newly diagnosed, nonbulky stages I and II Hodgkin lymphoma. Ninety-nine assessable patients received 6 cycles of doxorubicin 25 mg/m2, vinblastine 6 mg/m2, and gemcitabine 800 mg/m2 (1000 mg/m2 in first 6) on days 1 and 15 every 28 days. Computed tomography (CT) and positron emission tomography (PET) were performed before and after 2 and 6 cycles. Complete remission (CR)/CR unconfirmed was achieved in 72 of 99 patients (72.7%) and partial remission in 24 of 99 patients (24.2%). The CR rate was 81% when using PET criteria. Two patients have died of Hodgkin lymphoma progression. Median follow-up for nonprogressing patients is 3.3 years. The progression-free survival (PFS) at 3 years was 77% (95% confidence interval, 68%-84%). The relapse rate was less than 10% for patients with favorable prognostic factors. The 2-year PFS for cycle 2 PET-negative and-positive patients was 88% and 54%, respectively (P =.0009), compared with 89% and 27% for cycle 6 PET-negative and-positive patients (P =.0001). Although the CR rate and PFS were lower than anticipated, patients with favorable prognostic features had a low rate of relapse. Cycle 2 PET and cycle 6 PET were predictive of PFS. This clinical trial is registered at www.clinicaltrials.gov as #NCT00086801. © 2011 by The American Society of Hematology. |
| Journal Title: | Blood |
| Volume: | 117 |
| Issue: | 20 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2011-05-19 |
| Start Page: | 5314 |
| End Page: | 5320 |
| Language: | English |
| DOI: | 10.1182/blood-2010-10-314260 |
| PROVIDER: | scopus |
| PUBMED: | 21355087 |
| PMCID: | PMC3109706 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 23 June 2011" - "CODEN: BLOOA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work